Clinical, histopathological and therapeutic considerations in non-neoplastic abnormal uterine bleeding in menopause transition

Vol. 52 No. 3 Suppl., 2011
This supplement was not sponsored by Outside Organizations.

ROMANIAN JOURNAL of MORPHOLOGY and EMBRYOLOGY

Fl. Cornitescu, Florentina Tanase, Cristiana Simionescu, D. Iliescu

With the decline of ovarian hormonal function, from the fifth decade of life, women enter the menopause transition, during which bleeding becomes irregular in duration and time of occurrence. Secondary to ovarian dysfunction, developmental and maturation endometrial anomalies occur, which are clinically translated by abnormal uterine bleeding, which in many cases at this age can be caused by organic lesions (fibroma, polyps, endometritis, endometrial hyperplasia, adenomyosis, etc.). The retrospective study included a total of 256 patients with abnormal uterine bleeding in menopause transition. Statistics showed that the incidence of these types of bleeding increases with age (64.5%) and parity (30.5%), with symptoms consisting mostly in different clinical forms of abnormal uterine bleeding (62.1%), and leiomyomas prevailing at histopathological examination (49.6%). Progesterone replacement therapy was the first therapeutic choice for correcting these types of bleeding. Progesterone therapy is useful not only for therapeutic purposes to amend the bleeding, but also as a precaution against the development of endometrial carcinoma. Progestogens cancel the proliferative and mitogenic effect of estrogens, even when administered in sequential regimen 10-12 days per month.

Corresponding author: Florin Ion Cornitescu, Assistant Professor, MD, PhD, e-mail: gyn_col_corn@yahoo.com

Download PDF

ROMANIAN JOURNAL of MORPHOLOGY and EMBRYOLOGY

Ioana Gabriela Fita, Ana-Maria Enciu, B. P. Stanoiu

One of the most common problems encountered in a world characterized by demographic ageing is Alzheimer's disease (AD) with an estimated number of 35.6 million people affected in 2010 to 65.7 million in 2030. Under recognition and delayed diagnose create problems for people diagnosed with dementia, for their families and for entirely health system. Although there have been many breakthroughs and new insights into AD etiopathogeny in the last two decades, few steps have been made toward an accurate diagnosis but all steps point into one major direction namely "personalized medicine" that could represent a future perspective for AD patients. Starting with a more accurate diagnosis not of the clinical syndrome, but of underlying molecular defects, that may eventually lead to a personalized, more effective treatment.

Corresponding author: Bogdan Stanoiu, Lecturer, MD, PhD, e-mail: stanoiu.bogdan@yahoo.com

Download PDF
Download cover
Download contents

Journal archive